Multiple Sclerosis Drugs - Egypt

Egypt

Highlights

In Egypt, the revenue in the market of Multiple Sclerosis Drugs market is forecasted to reach US$23.29m by the year 2024.
It is expected that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 3.19%, leading to a market volume of US$27.24m by the year 2029.
When compared globally, United States is projected to generate the highest revenue, amounting to US$11.77bn in 2024.
Egypt's market for Multiple Sclerosis Drugs is experiencing a surge in demand due to an increasing prevalence of the disease in the country.

Key regions:

Market definitionIn-Scope/Out-of-scopeMarket structureReportsMethodology

The Multiple Sclerosis Drugs market in Egypt has been experiencing steady growth in recent years.

Customer preferences: Egypt has a high prevalence of Multiple Sclerosis, which has resulted in a growing demand for drugs that can help manage the symptoms of the disease. Patients in Egypt are increasingly looking for drugs that are effective, affordable, and have minimal side effects. As a result, there has been a shift towards the use of generic drugs, which are more affordable than branded drugs.

Trends in the market: The Multiple Sclerosis Drugs market in Egypt has been growing steadily due to the increasing prevalence of the disease in the country. There has been a growing demand for drugs that can help manage the symptoms of the disease, such as muscle stiffness, fatigue, and difficulty walking. The market has also seen a shift towards the use of generic drugs, which are more affordable than branded drugs. This has been driven by the high cost of branded drugs and the increasing availability of generic drugs in the market.

Local special circumstances: Egypt has a high prevalence of Multiple Sclerosis, which is a chronic disease that affects the central nervous system. The disease is more common in women than men and is usually diagnosed between the ages of 20 and 40. The exact cause of the disease is unknown, but it is believed to be an autoimmune disorder. The disease can be managed with drugs that help alleviate the symptoms, but there is no cure for the disease.

Underlying macroeconomic factors: The Egyptian economy has been growing steadily in recent years, which has resulted in an increase in disposable income for many Egyptians. This has led to an increase in demand for healthcare services, including drugs for the management of chronic diseases such as Multiple Sclerosis. The government has also been investing in the healthcare sector, which has led to an increase in the availability of drugs in the market. However, the high cost of branded drugs remains a challenge for many patients, which has led to a shift towards the use of generic drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.